Eric A. J. Hoste
YOU?
Author Swipe
Epidemiology, outcomes, and three-year quality of life in patients supported with VV-ECMO for critical COVID-19 infection Open
Three-year mortality after VV-ECMO for critical COVID-19 was 33.3%. Physical health was impaired, but mental health remained comparable to the general population, with relatively low anxiety and depression levels. RTW was possible in 56.5%.
View article: Nationwide Hypothermic Machine Perfusion for ECD and DCD Kidney Transplantation in Belgium: One-Year Outcomes and Impact on Transplant Rates and Budget Impact Analysis
Nationwide Hypothermic Machine Perfusion for ECD and DCD Kidney Transplantation in Belgium: One-Year Outcomes and Impact on Transplant Rates and Budget Impact Analysis Open
In September 2022, Belgium implemented a nationally reimbursed HMP service for all ECD and DCD kidneys procured and transplanted within the country. We retrospectively analyzed data from 242 kidney transplantations preserved with continuou…
View article: Potential of biomarker-based enrichment strategies to identify critically ill patients for emerging cell death interventions
Potential of biomarker-based enrichment strategies to identify critically ill patients for emerging cell death interventions Open
Critically ill patients admitted to the intensive care unit (ICU) frequently suffer from sepsis and severe multiple organ dysfunction with underlying widespread cell death. Pyroptosis and ferroptosis are regulated cell death forms that may…
View article: Renal tubular epithelial cells as an easily accessible biomarker for diagnosing AKI post cardiac surgery
Renal tubular epithelial cells as an easily accessible biomarker for diagnosing AKI post cardiac surgery Open
Purpose Acute kidney injury (AKI) is a common clinical complication of cardiac surgeries. Although urinary particle analysis is useful for differentiating AKI, its value in AKI diagnosis has not yet been well described. We sought to determ…
View article: Recommendations for clinical trial design in acute kidney injury from the 31st acute disease quality initiative consensus conference. A consensus statement
Recommendations for clinical trial design in acute kidney injury from the 31st acute disease quality initiative consensus conference. A consensus statement Open
The current lack of specific therapy for prevention or treatment of AKI demands refinement of future clinical trial design. Here we report the consensus findings of the 31st ADQI group meeting which has attempted to address these issues in…
Effect of a single small volume fluid bolus with balanced or un-balanced fluids on chloride and acid–base status: a prospective randomized pilot study (the FLURES-trial) Open
EC project number 2014/038.
View article: Correction: Phase-3 trial of recombinant human alkaline phosphatase for patients with sepsis-associated acute kidney injury (REVIVAL)
Correction: Phase-3 trial of recombinant human alkaline phosphatase for patients with sepsis-associated acute kidney injury (REVIVAL) Open
After the publication of the article, we have been informed that the name of a contributor in the list of REVIVAL investigators was given incomplete. He was given as “Patrick Honore” or “Honore P” but he should have been cited as “Patrick …
View article: Regional Practice Variation and Outcomes in the Standard Versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI) Trial: A Post Hoc Secondary Analysis
Regional Practice Variation and Outcomes in the Standard Versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI) Trial: A Post Hoc Secondary Analysis Open
OBJECTIVES: Among patients with severe acute kidney injury (AKI) admitted to the ICU in high-income countries, regional practice variations for fluid balance (FB) management, timing, and choice of renal replacement therapy (RRT) modality m…
View article: Immunological sub-phenotypes and response to Convalescent Plasma in COVID-19 induced ARDS: a secondary analysis of the CONFIDENT trial.
Immunological sub-phenotypes and response to Convalescent Plasma in COVID-19 induced ARDS: a secondary analysis of the CONFIDENT trial. Open
Background Convalescent Plasma (CP) reduced the mortality in COVID-19 induced ARDS (C-ARDS) patients treated in the CONFIDENT trial. As patients are immunologically heterogeneous, we hypothesized that clusters may differ in their treatment…
View article: CCL14 Predicts Oliguria and Dialysis Requirement in Patients with Moderate to Severe Acute Kidney Injury
CCL14 Predicts Oliguria and Dialysis Requirement in Patients with Moderate to Severe Acute Kidney Injury Open
Introduction: AKI is a frequent complication of critical illness and portends poor outcome. CCL14 is a validated predictor of persistent severe AKI in critically ill patients. We examined the association of CCL14 with urine output within 4…
View article: Crystalloids vs. colloids during minimally invasive oesophagectomy and their influence on postoperative acute kidney injury, mortality, and morbidity: a retrospective observational study
Crystalloids vs. colloids during minimally invasive oesophagectomy and their influence on postoperative acute kidney injury, mortality, and morbidity: a retrospective observational study Open
Background: Open oesophagectomy is associated with significant morbidity and mortality. Minimally Invasive Oesophagectomy (MIE) is proven to be an effective less invasive alternative. Appropriate intravenous (I.V.) fluid therapy during thi…
View article: Convalescent Plasma for Covid-19–Induced ARDS in Mechanically Ventilated Patients
Convalescent Plasma for Covid-19–Induced ARDS in Mechanically Ventilated Patients Open
The administration of plasma collected from convalescent donors with a neutralizing antibody titer of at least 1:160 to patients with Covid-19-induced ARDS within 5 days after the initiation of invasive mechanical ventilation significantly…
View article: Tight Blood-Glucose Control without Early Parenteral Nutrition in the ICU
Tight Blood-Glucose Control without Early Parenteral Nutrition in the ICU Open
In critically ill patients who were not receiving early parenteral nutrition, tight glucose control did not affect the length of time that ICU care was needed or mortality. (Funded by the Research Foundation-Flanders and others; TGC-Fast C…
Ferroptosis and pyroptosis signatures in critical COVID-19 patients Open
Critical COVID-19 patients admitted to the intensive care unit (ICU) frequently suffer from severe multiple organ dysfunction with underlying widespread cell death. Ferroptosis and pyroptosis are two detrimental forms of regulated cell dea…
View article: Phase 3 Trial of Recombinant Human Alkaline Phosphatase for Patients with Sepsis-Associated Acute Kidney Injury (REVIVAL)
Phase 3 Trial of Recombinant Human Alkaline Phosphatase for Patients with Sepsis-Associated Acute Kidney Injury (REVIVAL) Open
Purpose: Ilofotase alfa is a human recombinant alkaline phosphatase with reno-protective effects that showed improved survival and reduced MAKE90 in sepsis-associated acute kidney injury (SA-AKI) patients. ‘ REVIVAL’, was aphase 3 trial, c…
The effects of differing anticoagulant regimes on blood quality after cell salvage in coronary artery bypass grafting (CABG): a pilot study Open
Background Cell salvage reduces allogenic blood transfusion requirements in surgery. We present a pilot study exploring the impact of anticoagulant choice, citrate or heparin, on the quality of cell salvaged blood in adults undergoing coro…
View article: Potential of Urine Biomarkers CHI3L1, NGAL, TIMP-2, IGFBP7, and Combinations as Complementary Diagnostic Tools for Acute Kidney Injury after Pediatric Cardiac Surgery: A Prospective Cohort Study
Potential of Urine Biomarkers CHI3L1, NGAL, TIMP-2, IGFBP7, and Combinations as Complementary Diagnostic Tools for Acute Kidney Injury after Pediatric Cardiac Surgery: A Prospective Cohort Study Open
Acute kidney injury (AKI) is common after pediatric cardiac surgery (CS). Several urine biomarkers have been validated to detect AKI earlier. The objective of this study was to evaluate urine CHI3L1, NGAL, TIMP-2, IGFBP7, and NephroCheck® …